Literature DB >> 28323096

Nanoparticles as safe and effective delivery systems of antifungal agents: Achievements and challenges.

Ghareb M Soliman1.   

Abstract

Invasive fungal infections are becoming a major health concern in several groups of patients leading to severe morbidity and mortality. Moreover, cutaneous fungal infections are a major cause of visits to outpatient dermatology clinics. Despite the availability of several effective agents in the antifungal drug arena, their therapeutic outcome is less than optimal due to limitations related to drug physicochemical properties and toxicity. For instance, poor aqueous solubility limits the formulation options and efficacy of several azole antifungal drugs while toxicity limits the benefits of many other drugs. Nanoparticles hold great promise to overcome these limitations due to their ability to enhance drug aqueous solubility, bioavailability and antifungal efficacy. Further, drug incorporation into nanoparticles could greatly reduce its toxicity. Despite these interesting nanoparticle features, there are only few marketed nanoparticle-based antifungal drug formulations. This review sheds light on different classes of nanoparticles used in antifungal drug delivery, such as lipid-based vesicles, polymeric micelles, solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions and dendrimers with emphasis on their advantages and limitations. Translation of these nanoformulations from the lab to the clinic could be facilitated by focusing the research on overcoming problems related to nanoparticle stability, drug loading and high cost of production and standardization.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Amphotericin B; Amphotericin B (PubChem CID: 5280965); Antifungal drugs; Clotrimazole (PubChem CID: 2812); Dendrimers; Fluconazole (PubChem CID: 3365); Fungal infections; Griseofulvin (PubChem CID: 441140); Itraconazole (PubChem CID: 55283); Ketoconazole (PubChem CID: 456201); Liposomes; Micelles; Miconazole (PubChem CID: 4189); Nanoemulsions; Nanoparticles; Nystatin (PubChem CID: 6433272)

Mesh:

Substances:

Year:  2017        PMID: 28323096     DOI: 10.1016/j.ijpharm.2017.03.019

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  24 in total

1.  Antifungal Activity of Chitosan-Coated Poly(lactic-co-glycolic) Acid Nanoparticles Containing Amphotericin B.

Authors:  Daniel Brustolin Ludwig; Luciana Erzinger Alves de Camargo; Najeh Maissar Khalil; Marcos Ereno Auler; Rubiana Mara Mainardes
Journal:  Mycopathologia       Date:  2018-03-01       Impact factor: 2.574

Review 2.  Targeting the fungal cell wall: current therapies and implications for development of alternative antifungal agents.

Authors:  Sahar Hasim; Jeffrey J Coleman
Journal:  Future Med Chem       Date:  2019-04-17       Impact factor: 3.808

Review 3.  Novel Drug Delivery Strategies for the Treatment of Onychomycosis.

Authors:  Rupinder K Dhamoon; Harvinder Popli; Madhu Gupta
Journal:  Pharm Nanotechnol       Date:  2019

Review 4.  Vesicular nanocarrier based treatment of skin fungal infections: Potential and emerging trends in nanoscale pharmacotherapy.

Authors:  Shivani Verma; Puneet Utreja
Journal:  Asian J Pharm Sci       Date:  2018-08-16       Impact factor: 6.598

Review 5.  Current Insights on Antifungal Therapy: Novel Nanotechnology Approaches for Drug Delivery Systems and New Drugs from Natural Sources.

Authors:  Filipa Sousa; Domingos Ferreira; Salette Reis; Paulo Costa
Journal:  Pharmaceuticals (Basel)       Date:  2020-09-15

Review 6.  Biomaterials for the Prevention of Oral Candidiasis Development.

Authors:  Dan Cristian Gheorghe; Adelina-Gabriela Niculescu; Alexandra Cătălina Bîrcă; Alexandru Mihai Grumezescu
Journal:  Pharmaceutics       Date:  2021-05-27       Impact factor: 6.321

7.  Enhanced Efficacy of Thiosemicarbazone Derivative-Encapsulated Fibrin Liposomes against Candidiasis in Murine Model.

Authors:  Azmat Ali Khan; Amer M Alanazi; Nawaf Alsaif; Nasser Algrain; Tanveer Ahmad Wani; Mashooq Ahmad Bhat
Journal:  Pharmaceutics       Date:  2021-03-04       Impact factor: 6.321

Review 8.  Nanoparticles as a Solution for Eliminating the Risk of Mycotoxins.

Authors:  Pavel Horky; Sylvie Skalickova; Daria Baholet; Jiri Skladanka
Journal:  Nanomaterials (Basel)       Date:  2018-09-14       Impact factor: 5.076

Review 9.  Therapies and Vaccines Based on Nanoparticles for the Treatment of Systemic Fungal Infections.

Authors:  Brenda Kischkel; Suélen A Rossi; Samuel R Santos; Joshua D Nosanchuk; Luiz R Travassos; Carlos P Taborda
Journal:  Front Cell Infect Microbiol       Date:  2020-09-03       Impact factor: 5.293

10.  DNA Nanostructures in the Fight Against Infectious Diseases.

Authors:  David M Smith; Adrian Keller
Journal:  Adv Nanobiomed Res       Date:  2021-01-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.